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Effect of spironolactone on K+ homeostasis and ENaC expres-
sion in lymphocytes from chronic hemodialysis patients.
Background. Cardiac disease is the major cause of death in
hemodialysis patients (HD). It is now clear that aldosterone has
deleterious effects in the cardiovascular system. In the present
study, we evaluated the effects of an aldosterone-antagonist,
spironolactone, on the extrarenal regulation of potassium in
HD patients. Furthermore, to validate the effectiveness of
the spironolactone dose-design, we measured the expression
of Na+-channel (ENaC alpha subunit) in peripheral blood
mononuclear cells (PBMC), before and after a two-week course
of spironolactone.
Methods. The study design included a two-week baseline pe-
riod, followed by spironolactone treatment (50 mg three times
weekly for 15 days), and by a two-week washout period and then
a two-week placebo period. An oral K+ load (0.3 mEq/K+ kg
body weight plus carbohydrates) was administered at the end
of each period, and time-course of plasma potassium was evalu-
ated. ENaC expression in PBMC was assessed before and after
spironolactone.
Results. The maximal increase in plasma potassium after the
K+ carbohydrate load was: control 5.33 ± 0.88 mEq K+/L;
spironolactone 5.23 ± 0.68 mEq K+/L; placebo 5.38 ± 0.61 mEq
K+/L (N = 9). No patients developed hyperkalemia during the
spironolactone treatment period. ENaC expression was signifi-
cantly higher in all six HD patients studied, compared to control
subjects (P < 0.05). Treatment with spironolactone in HD pa-
tients reduced alpha subunit mRNA expression to values similar
to those of normal subjects.
Conclusion. Spironolactone may be considered for the treat-
ment of selected chronic HD patients. The effect of the drug
on a known target of aldosterone, the ENaC, demonstrates the
effectiveness of the drug to block aldosterone effects in nonep-
ithelial tissues.
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Aldosterone has an important role in the pathophys-
iology of cardiovascular diseases [1, 2]. In addition to
promoting sodium retention, aldosterone mediates car-
diac remodeling and myocardial collagen deposition [3–
5]. Patients with chronic renal failure (CRF) maintained
on hemodialysis (HD) die of heart disease at a rate of 20
to 40 times that of general population [6–9]. Several stud-
ies have involved aldosterone in cardiovascular disease of
patients with end-stage renal failure (ESRF) [10–12].
Recently, it has been shown that low doses of spirono-
lactone, a competitive inhibitor of aldosterone, admin-
istered to patients with chronic cardiomyopathy in the
Randomized Aldactone Evaluation Study (RALES)
trial, resulted in a dramatic reduction in the risk of
cardiac death and hospitalization [13]. Serious hyper-
kalemia occurred in 14 patients (2%) in the spironolac-
tone group and 10 patients in the placebo group [13].
Life-threatening hyperkalemia during combined therapy
with angiotensin-converting enzyme inhibitors (ACEIs)
and spironolactone has been reported in patients with
moderate CRF [14]. Knoll et al [15] have shown that
the use of ACE inhibitors or angiotensin receptor block-
ers is independently associated with an increased risk
of developing hyperkalemia in chronic HD patients.
Hyperkalemia is common in patients with end-stage renal
disease (ESRD) and accounts for considerable morbidity
and death [16].
The ability of patients with CRF to manage a load of
potassium is controversial. In patients with moderate to
advanced renal failure, some studies have postulated an
enhanced capacity in handling a potassium load, whereas
others have indicated a decrease in extrarenal potassium
tolerance [17–20].
Several factors are involved in internal potassium
homeostasis, such as insulin, catecholaminess, acid-base
balance, among others. Insulin plays a key role on skeletal
muscle uptake of potassium, and enhanced insulin sensi-
tivity in extrarenal potassium handling has been shown
in uremic rats [21]. The role of mineralocorticoids in
the muscular uptake of potassium is not well defined.
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Aldosterone levels in HD patients are reported in most
studies as normal or elevated [22]. Studies of Sugarman
and Brown [23] in anephric humans receiving an oral
potassium load after deoxycorticosterone or spironolac-
tone treatment suggest that mineralocorticoid enhanced
the removal of potassium from the extracellular space.
However, relatively high doses of spironolactone were
used in that study, as well as in the report of Vlassopoulus
et al [24]. Recent trials have demonstrated the safety of
low-dose spironolactone administration in chronic HD
patients [25, 26].
These observations are of special interest because
prevention of cardiovascular disease is essential in HD
patients. However, because these patients are prone to
hyperkalemia, a known side effect of spironolactone, this
treatment is not used in HD patients. The purpose of
the present study was to investigate the internal potas-
sium balance in HD patients treated with spironolactone.
We assessed whether a low dose of spironolactone (3 ×
50 mg/week) could be administered without induc-
ing an additional impairment in extrarenal potassium
homeostasis in chronic HD patients. Furthermore, the
effectiveness of spironolactone dose was assessed by
measuring mRNA expression of the sodium channel al-
pha subunit (ENaC), a classic target of epithelial aldos-
terone action.
METHODS
Patients
Study participants were recruited from the Nephrol-
ogy Dialysis Unit at Clı´nica Da´vila Center. Subjects
were anuric and had been in chronic HD therapy three
times per week, for at least 18 months. Subjects were ex-
cluded if they were experiencing symptomatic congestive
heart failure, uncontrolled hypertension (blood pressure
greater than 170/100 mm Hg), cirrhosis or chronic liver
disease, diabetes mellitus, or treatment with ACEIs, an-
giotensin receptor antagonist (ATR), or beta-blockers.
HD patients who had serum potassium >6 mEq/L were
excluded. None of the patients used ion-exchange resins
before or during the study. All the patients were under
standard diet, and no dietary changes were indicated dur-
ing the study. Besides our routine procedures and con-
trols, the protocol in this study included a dietary survey
and blood potassium measurements before each HD ses-
sion during the study period. The protocol was approved
by the Ethics Committees of both the Faculty of Medicine,
Universidad Los Andes, and of Clı´nica Da´vila. Written
informed consent was obtained from each subject prior
to study participation.
Study design
The design was a sequential, fixed-dose, doubled-blind,
and single-center trial. The study design included an ini-
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Fig. 1. Study design. Black bars denote administration of 50 mg al-
dactone, three times a week, or placebo, as indicated. Washout period
in between study medications was two weeks in duration. Potassium-
carbohydrate load was given at the end of each period. Blood samples
were taken as indicated in Methods.
tial baseline period as illustrated in Figure 1, followed
by a two-week treatment period with 50 mg spironolac-
tone (Aldactone; Pharmacia AG, Peapack, NJ, USA).
After a two-week washout period, placebo was adminis-
tered for 15 days. Aldactone or placebo was taken three
times/week immediately after the HD session to ensure
treatment adherence. At the end of the drug period and
just before a new HD session, an oral potassium load was
administered to test potassium tolerance of the patients
during basal, spironolactone, or placebo period. Aldac-
tone or placebo was given by the nurses in charge—not
related to the investigator team—according to the sched-
ule, three times/week immediately after the HD session
to ensure treatment adherence. Throughout the study,
measurements of serum potassium were performed be-
fore each dialysis session in the three aforementioned
conditions.
Standard dialysis conditions included polysulfone fil-
ters 1.8 m2 (F8), Qs = 300 mL/min, Qd = 500 mL/min;
140 mEq/L Na+, 2 mEq/L K+, 32 mEq/L HCO3−, and
100 mg/dL of glucose.
Oral potassium load
After a fasting period of 12 hours, each subject re-
ceived an oral mixed load of carbohydrates (Ensure
Plus, 0.5 g/kg body weight) with 0.3 mEq K+/kg of
dry body weight. The potassium load was adminis-
tered before the midweek HD session. Plasma sam-
ples were collected at −30, 0, 30, 60, 120 minutes
before dialysis started. Also, a final sample was taken
at the end of the dialysis (360 minutes) to measure
serum potassium. Plasma aldosterone, insulin, and glu-
cose were measured at the times indicated in Results.
Plasma renin activity (PRA) was measured before potas-
sium load.
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Laboratory analysis
Serum electrolytes were measured by ion selective
electrodes. Plasma aldosterone, insulin, and PRA levels
were assessed by radioimmunoassay.
Preparation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMC) from pa-
tients and healthy donors were separated from venous
blood collected in EDTA for preservation. Blood samples
were diluted in phosphate-buffered saline at 1 part blood
to 1 part buffer. PBMC were isolated by Histopaque 1077
(Sigma, St. Louis, MO, USA) density centrifugation, ac-
cording to instructions by the manufacturer (Boyum).
The interface mononuclear cell layer was washed twice
with phosphate-buffered saline.
ENaC mRNA expression of alpha subunit
To assess alpha mRNA expression, we isolated total
RNA from PBMC of a group of HD patients before and
after two weeks of aldactone treatment. Also, blood sam-
ples were taken from a group of healthy volunteers. Total
RNA was isolated from PBMC using Trizol (Invitrogen-
Life Technologies, Carlsbad, CA, USA) per specifi-
cations of the manufacturer. RNA concentration was
determined by spectrophotometry, and integrity of the
RNA was assessed by agarose gel electrophoresis. Total
RNA (1 lg) was reverse transcribed with random hex-
amers and Improm IITM Reverse Transcriptase (Promega
Corporation, Madison, WI, USA) at 42◦C for 60 minutes.
The synthesized cDNA was immediately stored at −20◦C.
Double-stranded cDNAs for the sodium channel (ENaC)
subunit were amplified as follows: 2 lL was mixed with
23 lL of 1× buffer solution [Tris-HCl 75 mmol/L, pH
8,8, (NH4)2SO4 20 mmol/L, Tween 20 0.01%] contain-
ing 0.2 mmol/L dNTP, a pair of flanking PCR primers
(0.1 lmol/L each), 2.5 U of Taq DNA polymerase (Fer-
mentas, Hanover, MD, USA), and 2.5 mmol/L MgCl2.
Primer sequences: sense primer (5′- GAA CAA CTC
CAA CCT CTG GAT GTC) and antisense primer (5′-
TCT TGG TGC AGT CGC CAT AAT C -3′) amplified
a 257 bp fragment. As an internal control, universal 18S
ribosomal RNA (Ambion, Austin, TX, USA) was used
for PCR amplification, to yield a 315-bp product. PCR
conditions were 94◦C for 3 minutes, 94◦C for 30 seconds,
60◦C for 30 seconds, and 72◦C for 30 seconds
for 30 cycles for EnaC, and 13 cycles for 18S in a
DNA Thermal Cycler (Mastercycler personal; Eppen-
dorf, Hamburg, Germany). The PCR products were sub-
jected to electrophoresis on 2.0% agarose gels containing
Gel star fluorescent dye for densitometry analysis (EDAS
120; Kodak Digital Science, Rochester, NY, USA).
Table 1. Baseline predialysis parameters at the end of each treatment
period
Variable Predrug Spirinolactone Placebo
Systolic blood pressure 146.6 ± 8 152.3 ± 7.4 151.7 ± 8.4
mm Hg
Diastolic blood pressure 78.2 ± 5.4 80.1 ± 5.7 84.0 ± 5.3
mm Hg
Plasma bicarbonate 22.5 ± 0.7 23.6 ± 2.3 23.8 ± 2.5
mEq/L
Plasma glucose 86.7 ± 3.1 89.4 ± 2.9 87.3 ± 4.1
mg/dL
Plasma potassium 4.53 ± 0.18 4.56 ± 1.13 4.67 ± 0.11
mEq/L
PRA ng/mL/h 1.7 ± 0.3 1.6 ± 0.6 1.5 ± 0.6
Aldosterone ng/dL 29.3 ± 9.7 37.5 ± 16.4 42.7 ± 14.6
Insulin lU/mL 43.7 ± 4.2 36.8 ± 4.0 36.5 ± 5.1
Value reported as mean ± SE of all patients (N = 9). No significant differences
between the three different conditions were observed.
Statistical analysis
The results were expressed as mean ± SE. Compari-
son between the three different treatment conditions was
performed using one-way analysis of variance (ANOVA)
and Student t test. Statistical significance was assessed at
values of P < 0.05.
To estimate the distribution of the potassium load
translocated to the intracellular space, first we calculated
the maximal rise in the measured plasma potassium after
the potassium load (K+max). The amount of potassium
present in the extracellular space was calculated by mul-
tiplying K+max by extracellular fluid space, estimated
as 20% of the body weight. Assuming no potassium loss
during the experimental period, the percentage of the re-
tained potassium translocated to the intracellular space
was calculated [17].
RESULTS
Patient characteristics
Nine patients that fulfilled the clinical criteria indicated
in Methods were included in the study (four female and
five males). All of them completed the three periods. They
had been in dialysis for at least 18 months (mean dialysis
time 39 months). Mean age was 43.1 years (range 16 to
76 years old). Mean plasma creatinine values were 9.2 ±
0.3 mg/dL during the study period.
Table 1 includes baseline clinical predialysis values of
the nine patients before the oral potassium load at the
end of each treatment. No side effects were noted during
the eight-week study period, and no patients required
discontinuation of the study for spironolactone-related
adverse events. Predialysis serum potassium levels were
measured throughout the study before each dialysis.
Measurements of serum potassium, performed before
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Fig. 2. Time course levels of plasma potassium during the oral potas-
sium and carbohydrate load. Results are the mean ± SEM in nine
hemodialysis (HD) patients during basal conditions, after two-week
spironolactone (50 mg three times weekly) and at the end of two-week
placebo. The oral load administered was 0.3 mEq potassium and 0.5 g
of Ensure Plus, per kg body weight.
each dialysis session, demonstrated no significant differ-
ences in predialysis plasma potassium levels in the study
period; plasma potassium with spironolactone treatment
fluctuated between 4.2 to 5.5 mEq K+/L during the two
weeks of drug administration. (Mean value ± SD: 4.52 ±
0.44).
Potassium load
An oral potassium and carbohydrate load (0.3 mEq
K+/kg of dry body weight) was administered to each pa-
tient before the midweek dialysis session under three
different conditions: predrug treatment, spironolactone,
and placebo, in order to compare extrarenal potassium
handling. As shown in Figure 2, plasma potassium val-
ues were elevated from 4.54 ± 0.15 mEq/L up to 5.33 ±
0.3 after 90 minutes of potassium-carbohydrate load dur-
ing the predrug period. Similar results were obtained at
the end of the spironolactone period, when a second oral
potassium-carbohydrate load was administered. During
the third phase, after a two-week washout period each
patient received placebo for two weeks, and finally, a
third potassium load was administered. Plasma potassium
time courses after the potassium-carbohydrate load are
included in Figure 2. As expected, the oral potassium load
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Fig. 3. Plasma aldosterone levels of hemodialysis (HD) patients before
and after potassium-carbohydrate load. Individual aldosterone levels
at baseline and after 60 minutes of K+ load in eight patients are rep-
resented in the control period (predrug) and at the end of two-week
spironolactone treatment, as indicated in Methods.
induced a significant increase in plasma potassium lev-
els, reaching peak values after two hours. No significant
differences in the maximal plasma potassium increments
were observed between the three conditions: predrug,
spironolactone, or placebo period. The percentage of the
oral potassium load translocated to the intracellular com-
partment was calculated as a way to estimate extrarenal
potassium tolerance in our patients in order to evaluate
the potential effect of spironolactone. Results were sim-
ilar in the three experimental conditions: 44.6 ± 6.2% in
the predrug period, 48.8 ± 9.3% after spironolactone, and
47.9 ± 9.6% after placebo.
As expected, plasma glucose was significantly elevated
after potassium-carbohydrate load. Peak values at 60
minutes were: predrug 105.6 ± 4.0 mg/dL; spironolac-
tone 111.0 ± 7.8 mg/dL; and placebo 110.4 ± 6.0 mg/dL.
Also, insulin levels were elevated with the oral potassium-
glucose load; a maximal value was obtained at 60 minutes.
No significant differences were observed between the
three conditions; peak plasma insulin levels at 60 minutes
were: predrug 57.5 ± 6.3 lU/mL; spironolactone 43.9 ±
6.6 lU/mL; and placebo 54.4 ± 10.1 lU/mL.
Aldosterone and potassium load
The plasma levels of aldosterone were measured under
basal and potassium load conditions during the predrug
period and after aldactone in eight HD patients. High
baseline plasma aldosterone levels were detected in four
HD patients (range 32.6 to 94.5 ng/dL); four HD patients
had aldosterone values in the normal range (mean 12.1 ±
2.9 ng aldosterone/dL). Spironolactone treatment did not
have significant effects of basal values in the patients, both
with normal or high plasma aldosterone, except for one
patient. Figure 3 includes the effect of potassium load on
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the aldosterone levels before and after spironolactone
treatment. As shown in the Figure 3, a tendency to in-
creased plasma aldosterone levels was observed.
Sodium channel expression on peripheral blood
mononuclear cells
To test the efficacy of the proposed spironolactone dose
and administration scheme, we measured the expression
of the ENaC alpha subunit, one of the major targets of al-
dosterone. For this study, we isolated blood mononuclear
cells from the blood of six HD patients. Also, a group
of four control normal subjects was studied. HD patients
had significantly higher mRNA of the alpha subunit of
ENaC compared to lymphocytes from normal subjects
(P < 0.05). The results are included in Figure 4. In all
HD patients studied, spironolactone treatment for two
weeks significantly decreased the amount of ENaC alpha
subunit mRNA (P< 0.05 vs. predrug treatment).
DISCUSSION
Serious hyperkalemia occurs in 10% of patients un-
dergoing hemodialysis, and it is held responsible for 3%
to 5% of deaths in these patients [16]. Hyperkalemia is
a known side effect of spironolactone [14, 27]. However,
recent studies have shown the safety of low-dose spirono-
lactone administration in dialysis patients [25, 26]. Hus-
sain et al used 25 mg of spironolactone administered daily
for 28 days, whereas Saudan et al utilized 12.5 mg or
25 mg of spironolactone three times a week. However,
none of the previous studies used a placebo control pe-
riod in the same patients. Saudan’s drug design is sim-
ilar to our study, and is based on the bioavailability of
spironolactone because its active metabolites canrenone
and 7-a methylspironolactone have a long half-life
(15 to 20 hours) and 95% plasma binding [28]. Half of
the metabolites are eliminated by the kidney; hence, we
hypothesized that 50 mg three times per week in non-
functional kidney patients would be at least equivalent to
the low-dose spironolactone used in the RALES study,
carried out in patients with normal or slightly impaired
renal function [13]. Treatment with spironolactone im-
mediately after the HD session would avoid eventual hy-
perkalemic episodes after the drug administration.
The results observed indicate that under the present
conditions no patients developed hyperkalemia. Fur-
ther, in nine patients, we administered a load of
potassium and carbohydrates equivalent to one reg-
ular meal before and after treatment with 50 mg of
spironolactone and/or placebo. There were no significant
differences in the extrarenal handling of potassium
among the three conditions. Intracellular translocation
of an ingested potassium load is the major route by
which the potassium absorbed after an acute load
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Fig. 4. Effect of spironolactone treatment on alpha ENaC mRNA ex-
pression in peripheral blood mononuclear cells. (A) Representative
agarose-gel electrophoresis of semiquantitative reverse transcription-
polymerase chain reaction (RT-PCR) studies for 18S and alpha ENaC
mRNA abundance in PBMC from control healthy volunteers (N),
hemodyalisis patients (HD) and HD patients after 14 days of spirono-
lactone treatment (SPIRO, 50 mg three times a week). (B) ENaC to 18S
ratio was calculated for each experiment and results from PBMC of four
healthy volunteers and six HD patients before and after spironolactone
treatment are presented as mean ± SE, ∗P < 0.05 HD vs. HD + SPIRO
and HD vs. healthy volunteers.
is retained within the body. A number of hormones
have either relatively well defined (e.g., insulin, cate-
cholamines), or more speculative roles, like aldosterone,
on the internal potassium balance. The interpretation
of the literature regarding the role of mineralocorti-
coids on extrarenal potassium metabolism is complicated
due to the well-known effect of aldosterone in the kid-
ney, and also by the use in other studies of nonphysiologic
doses of aldosterone or other mineralocorticoids [29].
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When renal function is compromised, plasma potassium
homeostasis involves increased colonic potassium secre-
tion [30, 31]. The factors responsible for maintaining the
colonic epithelium in its K+ hypersecretory state are un-
clear. Early observations suggested that hyperaldostero-
nism does not contribute to enteric K+ secretion in CRF
[32], and increased rectal K+ secretion has been demon-
strated in ESRD patients without secondary hyperaldos-
teronism [33]. However, other reports did not exclude a
role of aldosterone in mediating K+ secretion in large in-
testine of CRF patients [34]. Previous studies in anephric
patients found unaltered stool potassium excretion after
three days of DOCA or spironolactone administration
[23]. Plasma aldosterone levels have been shown to be
normal or high in CRF [30, 35–37]. In the present study,
half of the patients exhibited high plasma aldosterone.
Nevertheless, no significant differences were detected in
extrarenal potassium handling of HD patients with nor-
mal or high plasma aldosterone. Further, spironolactone
had no effect on the tolerance of HD patients to a potas-
sium load.
Other tissues implicated in potassium homeostasis that
could be influenced by aldosterone in CRF patients are
sweat and salivary glands. HD patients have decreased
sweat and saliva production [38, 39], reflecting compro-
mised gland function. Either normal [40] or increased K+
concentration [41] was found in sweat of HD patients.
Similarly, normal [40] or high salivary K+ concentration
was reported when comparing normal subjects to CRF
patients [23].
Aldosterone activates mineralocorticoid receptors in
renal tubules, which in turn increase the rate of synthe-
sis of several membrane proteins. It is well known that a
major effect of aldosterone in epithelial tissues is to in-
duce the Na-channel (ENaC) alpha subunit expression
[42]. In the kidney, aldosterone increases the abundance
of aENaC mRNA, but there is no change in the b and c
subunits [43]. Our group and others have shown the pres-
ence of mineralocorticoid receptors in the cardiovascular
system and the induction of the Na-pump by aldosterone
in rat blood vessels [44] Recently, it has been shown that
aldosteronism is associated with an activation of PBMCs
[45]. These cells have mineralocorticoid receptors, and
they express sodium channels [46]. All the patients stud-
ied had high levels of ENaC alpha subunit mRNAs.
Spironolactone treatment produced a dramatic effect
in alpha subunit expression in PBMC of HD patients.
After two weeks of spironolactone treatment (50 mg
three times a week) the amounts of alpha subunit mRNA
were similar to those of normal healthy subjects, even
though plasma aldosterone levels in HD patients were not
significantly modified. In our view, an important target to
monitor the dose of spironolactone is ENaC expression in
the PBMC, considering the emerging role of aldosterone
in mononuclear blood cells. According to this hypothe-
sis, the study dose-design could be considered an effective
strategy to ameliorate aldosterone effects in selected HD
patients. It is known that a large fraction of hemodialysis
patients are diabetics with insulin resistance, and ACE in-
hibitors or angiotensin receptor blockers are frequently
prescribed to HD patients. Diabetes mellitus and serum
creatinine are the main predictors of hyperkalemia for pa-
tients under treatment with ACEIs [47]. Combination of
ACE inhibitors and spironolactone can increase the risk
of hyperkalemia in non-HD patients with renal insuffi-
ciency [48], and the use of ACE inhibitors or angiotensin
receptor blockers is independently associated with an in-
creased risk of developing hyperkalemia in chronic HD
patients [49]. Other studies in azotemic patients have
demonstrated modest increases in kalemia associated
with the use of ramipril, captopril, or lisinopril [50–52].
Previous studies from our group have shown enhanced
insulin sensitivity in extrarenal potassium handling in ure-
mic rats [21]. Also, extrarenal potassium balance was not
significantly altered in non–insulin-dependent hyperten-
sive diabetic patients challenged with a similar potassium-
carbohydrate load protocol [53]. Nonetheless, it would be
important to perform future studies to evaluate the safety
of low-dose mineralocorticoid receptor blockers in dia-
betic HD patients and HD patients under ACE inhibitors.
CONCLUSION
Our results on extrarenal potassium regulation demon-
strate that spironolactone can be administered safely, un-
der our study design, to stable HD patients. Furthermore,
the measurement of the Na-channel alpha subunit ex-
pression could be useful to monitor the effectiveness of
the treatment with spironolactone, not only for CRF pa-
tients on hemodialysis, but also for other pathologic con-
ditions involving high aldosterone levels.
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